via University of York
An international team of scientists have discovered a molecule which prevents tumour cells spreading from a primary cancer site to colonise other sites in the body.
The multidisciplinary research team, from the University of York, Leiden University and Technion (Israel Institute of Technology) discovered that the small, sugar-like molecule maintains the integrity of tissue around a tumour during cancer. They have shown the sugar-like molecules markedly reduce cancer spread in mice, paving the way for development towards clinical application.
Invade
Metastasis, the spread of cancer cells to distant sites in the body, is what makes cancer so lethal. Metastasis formation depends on the ability of cancer cells to detach from the primary tumour site, and invade through blood vessel walls and tissue barriers to reach secondary sites of growth. This metastatic invasion process requires biological molecules called enzymes, which digest proteins and sugars in the space around cells, enabling cancer cells to pass through the subsequent gaps.
One abundant class of sugar that surrounds cells are the heparan sulfates, which are long chain-like molecules that help stabilise the integrity of the extracellular space. Heparan sulfate sugars are digested by an enzyme called heparanase, which acts to chop up the ‘chains’ and thereby weaken the space around cells.
Target
Metastatic cancer cells produce large amounts of heparanase enzyme, which helps them to spread around the body. Inhibiting heparanase is therefore a major target for anti-cancer therapy.
The researchers developed and tested a new sugar-like molecular that reacts with the enzyme heparanase, whose 3-D structure was first solved by the York group. Once the new molecule is bound, the heparanase enzyme is unable to bind or cut heparin sugar chains around cells. In this way, the tissue around cells remains firm and inaccessible to dislodged cells.
At York, Professor Gideon Davies and Dr Liang Wu from the Department of Chemistry showed how the enzyme inhibitor inhibits heparanase. The research team is now looking at how the molecule can be further improved.
Evolve
Professor Davies said: “It has been brilliant to see the work develop from fundamental studies of enzyme structure and function and evolve into small molecules with potent anti-cancer activities. It is really exciting”
Researchers at Technion studied the new molecule in mouse models of lung cancer, breast cancer and blood cancer. While it is still too early to determine whether the new molecule will reach clinical application, the results are promising and the institutes involved have already applied for a patent on the molecule.
Safe
Lead author of the study Professor Hermen Overkleeft from Leiden University said: “Now we have to find out whether the compound is stable, safe for the human body, ends up in the right place in sufficient quantities, and so on. That takes a couple of years, it may come to nothing and someone has to be willing to take that financial risk.
“Our molecule is one of the few agents that can inhibit heparanase tightly and specifically. Medicine has a preference for small, simple molecules like this.”
Original Article: Chemists create molecule that prevents tumour cells from spreading
More from: University of York | Leiden University | Technion-Israel Institute of Technology
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Metastasis
- Skin cancer: New treatment could be available within decade after major discovery about how melanoma spreads
Scientists caution that more research is needed by say they are hopeful that effective new drugs could be available to curb the spread of cancer in the coming years ...
- A new approach for detecting tumor heterogeneity to assess breast cancer patient outcomes
Tumor heterogeneity refers to the presence of a variety of distinct cell types within a tumor. High tumor heterogeneity is thought to contribute to breast cancer progression and metastasis, or ...
- Sentinel Lymph Node Biopsy Can Be Therapeutic in Melanoma Patients
Sentinel lymph node (SLN) biopsy without completion lymph node dissection (CLND) led to regional nodal disease control in melanoma patients, even those with risk factors for in-basin recurrence, ...
- 'RNA fishing' reveals new driver of melanoma malignancy and metastasis
Center for Genomic Regulation. (2022, August 3). 'RNA fishing' reveals new driver of melanoma malignancy and metastasis: PDIA6 constitutes a new therapeutic target for malignant melanoma.
- Study Discovers Common Mechanism Behind Cancer Metastasis, Cardiovascular Disease
New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that ...
Go deeper with Google Headlines on:
Metastasis
Go deeper with Bing News on:
Inhibiting heparanase
- Mechanisms of Disease: Angiogenesis In Urologic Malignancies
[35] Clinical trials in which EGFR is inhibited by monoclonal antibodies or tyrosine kinase inhibitors are ongoing. Thrombospondin exerts its effects via inhibition of VEGF and bFGF, and is the ...
- Small molecule prevents tumour cells from spreading
Metastatic cancer cells produce large amounts of heparanase enzyme, which helps them to spread around the body. Inhibiting heparanase is therefore a major target for anti-cancer therapy.
- University of York: Chemists create molecule that prevents tumour cells from spreading
An international team of scientists have discovered a molecule which prevents tumour cells spreading from a primary cancer site to colonise other sites in the body. The multidisciplinary research team ...
- Chemists create molecule that prevents tumor cells from spreading
Identifying the target Metastatic cancer cells produce large amounts of heparanase enzyme, which helps them to spread around the body. Inhibiting heparanase is therefore a major target for anti ...
- The Biochemical journal
A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Insulin-like growth factor II peptide ...